Difference between revisions of "Thyroid cancer, RET-positive"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.") |
|||
Line 67: | Line 67: | ||
|- | |- | ||
|} | |} | ||
+ | ''Note: Wirth et al. 2020 only mentioned the 160 mg dosing; the FDA label includes weight-based recommendations.'' | ||
<div class="toccolours" style="background-color:#fdcdac"> | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Biomarker eligibility criteria==== | ====Biomarker eligibility criteria==== | ||
Line 80: | Line 81: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''LIBRETTO-001:''' Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. [https://doi.org/10.1056/nejmoa2005651 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32846061/ PubMed] [https://clinicaltrials.gov/study/NCT03157128 NCT03157128] | + | # '''LIBRETTO-001:''' Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. [https://doi.org/10.1056/nejmoa2005651 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/32846061/ PubMed] [https://clinicaltrials.gov/study/NCT03157128 NCT03157128] |
[[Category:Thyroid cancer regimens]] | [[Category:Thyroid cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Endocrine cancers]] | [[Category:Endocrine cancers]] | ||
[[Category:Head and neck cancers]] | [[Category:Head and neck cancers]] |
Revision as of 12:09, 10 January 2024
Section editor | |
---|---|
Unfilled If you are interested in this role, please contact us at [email protected]. |
Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.
2 regimens on this page
2 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Thyroid Carcinoma.
Advanced or metastatic disease
Pralsetinib monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Subbiah et al. 2021 (ARROWRET) | 2017-2020 | Phase 1/2 (RT) |
Note: this trial is denoted as ARROWRET to distinguish from other trials of the same name. This is the phase 2 dosing.
Biomarker eligibility criteria
- RET fusion positive
References
- ARROWRET: Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. Epub 2021 Jun 9. Erratum in: Lancet Diabetes Endocrinol. 2021 Oct;9(10):e4. link to original article PubMed NCT03037385
Selpercatinib monotherapy
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Wirth et al. 2020 (LIBRETTO-001) | 2017-2019 | Phase 1/2 (RT) |
Note: Wirth et al. 2020 only mentioned the 160 mg dosing; the FDA label includes weight-based recommendations.
Biomarker eligibility criteria
- RET fusion-positive thyroid cancer
- RET-mutant medullary thyroid cancer
Targeted therapy
- Selpercatinib (Retevmo) by the following weight-based criteria:
- Less than 50 kg: 120 mg PO twice per day
- 50 kg or more: 160 mg PO twice per day
Continued indefinitely
References
- LIBRETTO-001: Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. link to original article contains dosing details in manuscript PubMed NCT03157128